Betagenon /Balticgruppen Bio AB announces the start of a bridging PK and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator compound O304 STOCKHOLM, Aug. 17, 2020 ...
Isomeranzin (ISM) binds to Gnas, activating adenylyl cyclase and elevating intracellular cAMP levels. This activation ...
The New York based biotech company announces launch of Amplifier Therapeutics to develop the clinical stage pan-AMPK activator, ATX-304 NEW YORK, March 14, 2023 /PRNewswire/ -- Cambrian Bio, a ...
Adenosine monophosphate (AMP)-activated protein kinase (AMPK) plays an important role in cellular energy homeostasis, helping in growth regulation and metabolic reprogramming in eukaryotes. The AMPK ...
Please provide your email address to receive an email when new articles are posted on . Poxel SA announced positive results for the phase 2a trial of PXL770 for the treatment of nonalcoholic ...
LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 ...
Globally ~40% of type 2 diabetes (T2D) patients develop diabetic kidney disease (DKD), and diabetes is the leading cause of end stage renal disease, requiring dialysis or a kidney transplant. Standard ...
Credit: Shutterstock. PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. The Food and Drug Administration (FDA) has granted Fast Track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback